In a mouse model of multiple sclerosis (MS), the administration of a CXCR7 antagonist prevented inflammatory damage to axons, preserving the axonal integrity and improving the behavioral recovery (Cruz-Orengo et al., 2011). This evidence concerns the gene ACKR3 and myeloid sarcoma.